High-sensitivity CRP · heart risk
High-Sensitivity CRP: The Inflammation Number Your Cholesterol Panel Leaves Out
High-sensitivity C-reactive protein (hs-CRP) is a blood test for low-grade inflammation, read against heart risk. Under 1 mg/L is lower risk, 1 to 3 mg/L is average, and above 3 mg/L is higher. A result above 10 usually means an infection or injury, and the test is repeated once you are well.
A standard cholesterol panel tells you how much fuel is in the pipes. It does not tell you whether anything is burning. hs-CRP is one of the few routine tests that reads the burning, which is why it is worth understanding even if nobody has ordered it for you yet.
Is a CRP test the same as a high-sensitivity CRP test?
Same molecule, different range. C-reactive protein is made by the liver when the body’s inflammatory signals rise. A standard CRP test is built to catch large spikes, the kind seen with pneumonia or a flare of arthritis, where values run in the tens or hundreds. The high-sensitivity version reads the low range accurately, the region under 10 mg/L where the slow, smoldering inflammation tied to heart disease lives.
The heart-risk bands come from a joint statement by the Centers for Disease Control and Prevention and the American Heart Association: under 1 mg/L lower risk, 1 to 3 mg/L average, above 3 mg/L higher. Measura’s laboratory panels report hs-CRP against those same bands, and flag a value above 10 for a repeat once any infection or injury has passed.
Does inflammation cause heart attacks, or just show up next to them?
For decades this was argued as chicken and egg. A 2017 trial settled most of it. CANTOS enrolled 10,061 people who had already had a heart attack and still had an hs-CRP of 2 mg/L or more. They received canakinumab, an antibody that blocks one inflammatory signal, interleukin-1 beta, or placebo. The drug did not lower cholesterol at all. At the 150 mg dose it still cut repeat heart attacks, strokes and cardiovascular deaths by 15% compared with placebo over a median of 3.7 years.
It also raised the rate of fatal infections, and it is not a medicine anyone uses for prevention. Its value is the proof: turn down inflammation alone, change nothing else, and fewer arteries close. Inflammation is not a bystander at the scene. It is one of the arsonists.
What raises hs-CRP besides the heart?
Almost everything that makes fat sick. The usual list:
- Visceral fat. Fat packed around the organs releases the inflammatory messengers that tell the liver to make CRP. See fat mass versus sick fat.
- Insulin resistance. High insulin and inflammation feed each other in a loop.
- Short or broken sleep, smoking, untreated gum disease and an inflamed gut.
- Chronic pain and nerve injury. Damaged nerves sit in inflamed tissue, and the cytokines and chemokines released there sensitize pain fibers and keep pain going. In older adults followed for six and a half years, the link between obesity and new neuropathy ran partly through inflammatory chemokines measured in the blood.
That last item is why pain and the heart travel together. In the UK Biobank, 475,171 adults were followed for a median of seven years. Chronic localized pain carried a 14% higher adjusted risk of cardiovascular disease and chronic widespread pain a 48% higher risk, after accounting for the usual risk factors, inflammatory diseases and anti-inflammatory medication. A person who hurts every day and has a “slightly high” hs-CRP is not describing two problems.
Can a normal hs-CRP still miss inflammation?
Yes, and this is the part most write-ups skip. When surgeons compared fat sampled from the surface of the heart with fat under the skin in 42 bypass patients, the heart’s fat was making far more inflammatory messengers. The authors added a warning: blood levels of inflammatory markers may not reflect the inflammation happening locally in that tissue. hs-CRP is a citywide smoke reading. A fire in one basement can burn without moving it much. That is the subject of fat around the heart.
So a low number is reassuring, not absolving. It belongs next to waist, body composition, insulin and arterial testing, never on its own.
What does an hs-CRP of 2 or more change?
The 2019 American College of Cardiology and American Heart Association prevention guideline lists an hs-CRP of 2.0 mg/L or higher as a “risk-enhancing factor,” alongside metabolic syndrome, chronic inflammatory conditions and a low ankle-brachial index. In that guideline the enhancer’s main job is to tip a borderline patient toward a statin.
The reading here is different. The statin trials proved benefit in the populations they enrolled, and those populations rarely looked like the patient with chronic pain, sick fat and three other diagnoses. An elevated hs-CRP is a question about where the fire is coming from. Lowering cholesterol in response to a fire is blaming the fire department for the fire. If you take a statin, review it with the physician who prescribed it; do not stop it on your own. But do ask what is feeding the inflammation.
Can you bring hs-CRP down?
Usually, by shrinking the source. In STEP-HFpEF, adults with obesity-related heart failure who lost an average of 13.3% of their body weight on semaglutide saw CRP fall by 43.5%, compared with 7.3% on placebo. The inflammation followed the fat. GLP-1 medicines may be part of your solution for specific problems, chosen after an evaluation, and the same direction can be reached by the slower road: fewer acellular carbohydrates and industrial seed oils, protein and resistance training to protect muscle, a fixed eating window, and seven to eight hours of dark, uninterrupted sleep. Each of those pushes insulin down or helps it work, and lower insulin lets inflamed fat empty.
Dr. Padda draws his own blood during experiments on himself, because he would rather take the biological hit than recommend something he has not measured. The same rule applies to you: get the number, change one thing, and repeat it in about three months to see whether it moved.
What should you ask for alongside hs-CRP?
Inflammation is the last link in a chain. Ask for the earlier links too, in the order they usually move:
- LP-IR, the lipoprotein insulin-resistance score, which rises before HbA1c does.
- Fasting insulin, reported on its own and as HOMA-IR. In Dr. Padda’s clinic a fasting insulin above 10 µIU/mL is treated as high risk.
- GGT, an under-used early marker of fatty liver. His clinic’s risk cutoff is above 20 U/L, well under the lab’s flag.
- Oxidized LDL and the omega-3 index with the omega-6 to omega-3 ratio, which together read how much hyperprocessed food is in the diet.
- hs-CRP, read against the bands above.
- 25-OH vitamin D, homocysteine, and B12 with methylmalonic acid or holotranscobalamin, because a serum B12 in the normal range can still hide a deficiency that injures nerves.
Then pair the chemistry with the body: body composition, arterial stiffness and ankle-brachial index. For how hs-CRP fits the full risk estimate, see what the ASCVD calculator misses.
If you have chest pain, pressure, sudden shortness of breath or new weakness on one side, call 911. Measura testing is for planning, not emergencies.
Frequently asked questions
Should I fast before an hs-CRP test?
Fasting does not change hs-CRP much, but it is usually drawn with fasting insulin and lipids, which do need a fast. What matters more is timing: do not test during a cold, a flare or the week after an injury, because those push the number up for reasons unrelated to your arteries.
My hs-CRP was 12. Do I have heart disease?
Not necessarily. A value above 10 mg/L usually reflects an infection, an injury or an inflammatory flare. The standard approach is to repeat it once you are well and read the repeat against the heart-risk bands.
Does chronic pain raise CRP?
It can. Painful nerve and tissue injury involve inflammatory signaling, and the conditions that feed chronic pain, such as visceral fat, insulin resistance and poor sleep, raise CRP too. A persistently elevated hs-CRP in someone with daily pain is a reason to look at the whole terrain, not just the painful spot.
Find out where your inflammation comes from
An hs-CRP result is a question, not an answer. Pair it with body composition, insulin and vascular testing to see what is feeding it.
4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.
References
- Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., et al. (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107(3), 499-511. https://doi.org/10.1161/01.cir.0000052939.59093.45 (PMID 12551878)
- Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., et al. (2017). Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 377(12), 1119-1131. https://doi.org/10.1056/NEJMoa1707914 (PMID 28845751)
- Ellis, A., & Bennett, D. L. H. (2013). Neuroinflammation and the generation of neuropathic pain. British Journal of Anaesthesia, 111(1), 26-37. https://doi.org/10.1093/bja/aet128 (PMID 23794642)
- Schlesinger, S., Herder, C., Kannenberg, J. M., Huth, C., Carstensen-Kirberg, M., Rathmann, W., et al. (2019). General and Abdominal Obesity and Incident Distal Sensorimotor Polyneuropathy: Insights Into Inflammatory Biomarkers as Potential Mediators in the KORA F4/FF4 Cohort. Diabetes Care, 42(2), 240-247. https://doi.org/10.2337/dc18-1842 (PMID 30523031)
- Rönnegård, A.-S., Nowak, C., Äng, B., & Ärnlöv, J. (2022). The association between short-term, chronic localized and chronic widespread pain and risk for cardiovascular disease in the UK Biobank. European Journal of Preventive Cardiology, 29(15), 1994-2002. https://doi.org/10.1093/eurjpc/zwac127 (PMID 35727954)
- Mazurek, T., Zhang, L., Zalewski, A., Mannion, J. D., Diehl, J. T., Arafat, H., et al. (2003). Human epicardial adipose tissue is a source of inflammatory mediators. Circulation, 108(20), 2460-2466. https://doi.org/10.1161/01.CIR.0000099542.57313.C5 (PMID 14581396)
- Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., et al. (2019). 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140(11), e596-e646. https://doi.org/10.1161/CIR.0000000000000678 (PMID 30879355)
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., et al. (2023). Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 389(12), 1069-1084. https://doi.org/10.1056/NEJMoa2306963 (PMID 37622681)
Related reading
- Obesity and Heart Disease: The Weight of Fat and the Sickness of Fat
- Does Sugar Cause Inflammation? What Your Numbers Can Show
- Laboratory Panels
Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed .